Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.

The Israeli pharmaceutical giant is accelerating its growth strategy and adding to its portfolio a groundbreaking treatment for Tourette syndrome in children.

Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the ...

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ...

While few companies are willing to put their money down on "exceptionally difficult" neurological conditions like Tourette syndrome (TS), Emalex Biosciences is now ready for the challenge thanks to a ...

CHICAGO, March 1, 2023 /PRNewswire/ -- Emalex Biosciences announced that the first patient was dosed in its Phase 3 clinical trial evaluating ecopipam for the treatment of Tourette Syndrome.

Tourette syndrome causes involuntary muscle and vocal tics that can be treated with several drugs, but most of them work the same way. Emalex Biosciences’ experimental drug hits a different central ...

CHICAGO--(BUSINESS WIRE)--An open-label extension study of 121 pediatric patients with Tourette syndrome evaluated the safety profile of the investigational drug ecopipam for up to 12-months of ...

Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in development for the ...